Fit_Tokens

A new vaccine against pancreatic cancer, one of the deadliest cancers, prompted an immune response in 99% of the patients whose responses could be measured. Most pancreatic cancers are driven by mutations in the KRAS gene. The vaccine, called camupepimut and developed by Elicio Therapeutics, is designed to train the immune system's T cells to recognize seven of the most common KRAS mutations. In a phase 2 trial led by Mayo Clinic oncologist Ben George, 144 patients who had already completed surgery and chemotherapy were randomly assigned to receive the vaccine or to be observed without it. Among the 90 vaccinated patients who could be evaluated, 89 developed T cells that targeted mutated KRAS. In more than 80% of them, the response was over nine times stronger than at baseline. Patients with the strongest immune responses tended to remain cancer-free for longer. A larger phase 3 trial is planned, and it may include booster doses and combinations with other drugs. [George B, Singh H, Devoe CE, et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Nature Medicine. 2026. DOI: 10.1038/s41591-026-04734-7]

Turtle relaxing on a Sunday.

A massive clinical trial evaluating 830 young children has confirmed that brushing a specialized liquid medication directly onto active dental caries can halt the progression of tooth decay. The noninvasive procedure completely eliminates the need for conventional dental drilling, local anesthetic injections, or sedative drugs during application, with each individual tooth requiring only a few seconds of contact to receive the full therapeutic dose. Known scientifically as silver diamine fluoride, or SDF, the experimental formulation successfully arrested the decay process in more than half of all treated lesions, whereas only about one-fifth of the lesions in the parallel placebo group spontaneously ceased worsening. Led by investigators at the University of Michigan, the Phase III study tested a 38 percent concentration of the solution on children experiencing advanced decay throughout their primary dentition. The young participants were randomly assigned to receive either the active chemical compound or an inactive placebo substance, with a secondary follow-up application administered six months into the protocol. The medicine relies on a dual mechanism where the silver component aggressively neutralizes decay-causing oral bacteria and the fluoride component fortifies the remaining enamel and dentin matrix against further acid degradation. Instead of physically excavating compromised biological tissue to prepare a tooth for a standard composite or amalgam filling, the topical agent functions strictly to freeze the lesion in place, though it lacks the structural ability to regenerate missing parts of the tooth. Clinical deployment of the treatment involves a highly visible aesthetic compromise because the silver compound permanently oxidizes the active decay site, turning the internal walls of the cavity completely black. This profound discoloration poses cosmetic concerns that can be particularly striking when the medication is applied to anterior teeth near the front of the mouth. Nevertheless, the speed and ease of application provide a crucial therapeutic alternative for toddlers and young children who struggle to tolerate prolonged, high-anxiety traditional dental work, enabling providers to safely manage early childhood caries while delaying or bypassing invasive operational procedures. Parents and practitioners must recognize that the chemical approach does not resolve every single cavity and demands continuous, long-term monitoring. Certain treated structures will inevitably require subsequent structural fillings, crowns, or alternative restorative procedures to regain full functionality. Although this cost-effective technique has enjoyed extensive international utilization for several decades, the rigorous data published in JAMA Pediatrics provides the necessary foundational proof within the United States to highlight how a basic, brush-on solution can rapidly bring severe childhood decay under control across diverse populations. [Fontana, M., Moursi, A., Gonzalez-Cabezas, C., et al. (2026). Efficacy of Silver Diamine Fluoride on Young Children With Severe Early Childhood Caries: A Randomized Clinical Trial. JAMA Pediatrics, 180(9), 942. doi:10.1001/jamapediatrics.2026.2567]

«The great disappointment»